IncobotulinumtoxinA Injection Uses, Dosage, Side Effects and Interactions
Xeomin
Xeomin is a brand of incobotulinumtoxina injection that comes as an injection.
IncobotulinumtoxinA is a botulinum toxin injection that relaxes overactive muscles and reduces saliva-gland activity, used for chronic drooling, muscle stiffness and spasm conditions, and temporary improvement of upper facial lines.
Quick links
Ask Anything About IncobotulinumtoxinA InjectionType a question in your own words. Answered from its FDA label in seconds.Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.
IncobotulinumtoxinA Injection in Short
- Drug classes Acetylcholine Release Inhibitor; Neuromuscular Blocker How the FDA classifies it
What it treatsXeomin (incobotulinumtoxinA) is injected to treat several conditions: Chronic sialorrhea (long-term drooling) in people 2 years and older Upper limb spasticity (muscle stiffness in the arm) in people 2 years and older Cervical dystonia (painful neck muscle spasms) in adults Blepharospasm (involuntary eyelid spasms) in…
- How you get it Prescription only
- Comes asInjection (into a muscle)
- The FDA’s strongest warningBoxed warning The FDA’s most serious alert. Read what it says
The Pharmacist’s Take
Xeomin (incobotulinumtoxinA) is a botulinum toxin, on the U.S. market since about 2010, that blocks the nerve signal acetylcholine so treated muscles relax and salivary glands quiet down; specialists use it for chronic drooling, arm stiffness (spasticity), cervical dystonia (neck spasms), blepharospasm (eyelid spasms) and temporary smoothing of upper facial lines. Most people tolerate it well, noticing injection site pain or bruising, dry mouth or headache, though neck and eyelid treatments can bring nearby weakness, swallowing trouble or a drooping lid. Its boxed warning is that the toxin can spread beyond the injection area, so get emergency care for trouble swallowing, speaking or breathing, even weeks later.
Key Takeaways From the HelloPharmacist Team
- Expect a trained professional to inject it, with repeat sessions no sooner than every 12 weeks (every 16 weeks for drooling).
- Results usually build over several days and fade over a few months as new nerve endings form, which is why treatment repeats.
- Tell each prescriber you get Xeomin, since its units do not convert to other botulinum toxins and another within months can overweaken muscles.
- Before each session, mention any swallowing or breathing trouble, a nerve or muscle condition, or an infection where the injection goes.
FDA Boxed WarningThe FDA’s strongest safety alert. Read what it says about IncobotulinumtoxinA Injection.
The toxin’s effects can spread from the injection site to other parts of the body and cause serious, even life-threatening problems.
Symptoms can include general weakness, double or blurred vision, drooping eyelids, trouble swallowing or speaking, loss of bladder control and trouble breathing. They can start hours to weeks after injection, and deaths have been reported.
The risk is probably greatest in children treated for spasticity, but adults can be affected too, especially those with underlying conditions. Seek immediate medical care if you have swallowing, speech or breathing problems.
Patient Information Guide for IncobotulinumtoxinA Injection
What It’s Used For
Xeomin (incobotulinumtoxinA) is approved for these uses:
- Chronic sialorrhea (long-term drooling) in people 2 years and older
- Upper limb spasticity (arm muscle stiffness) in people 2 years and older
- Cervical dystonia (neck muscle spasms) in adults
- Blepharospasm (involuntary eyelid spasms) in adults
- Temporary improvement of moderate to severe glabellar (frown) lines, horizontal forehead lines and lateral canthal lines (crow’s feet) in adults
How It Works
Xeomin enters the ends of nerves that control muscles and salivary glands. There it cuts a protein called SNAP25 that nerves need to release acetylcholine. Without that chemical signal, the muscle or gland quiets down.
The effect is not permanent. Over time, new nerve endings form and signaling returns.
Drug Class
Drug Class
- Acetylcholine Release Inhibitor
- Neuromuscular Blocker
Detailed classifications and sources
The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.
Drug Class
Established Pharmacologic Class (EPC)- Acetylcholine Release Inhibitor
- Neuromuscular Blocker
The main drug class the FDA gives it. It is the class named on the drug’s label.
How It Works
Mechanism of action (MoA)- Acetylcholine Release Inhibitors
What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.
What It Does in the Body
Physiologic effect (PE)- Neuromuscular Blockade
A change it makes in how the body works.
Chemical Family
Chemical structure (CS)None listed for IncobotulinumtoxinA Injection in the FDA’s index.
The chemical family it belongs to, by its structure.
The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. Read the FDA’s definitions. Reference only, not medical advice.
Dosage
Xeomin is given by injection by a trained professional, into muscles or into salivary glands for drooling. It is not taken by mouth, so food does not apply.
- Repeat treatments are spaced out, usually at least 12 to 16 weeks depending on the condition.
- Facial lines should be retreated no more often than every three months.
- Dose and injection sites are individualized to you.
If you miss a scheduled visit, ask your prescriber when to reschedule.
Typical Doses
Your prescriber chooses your dose, so take it exactly as prescribed.
Chronic drooling
Adults Usual dose 100 Units per treatment session
- 100 Units per treatment session: 30 Units per parotid gland and 20 Units per submandibular gland (60 Units total parotid, 40 Units total submandibular), no sooner than every 16 weeks
Children 12 kg or more Usual dose 20 Units total per session
Step by step
- Parotid gland 6 Units each side (0.24 mL)
- Submandibular gland 4 Units each side (0.16 mL)
- Total 20 Units
Children 15 kg or more Usual dose 30 Units total per session
Step by step
- Parotid gland 9 Units each side (0.36 mL)
- Submandibular gland 6 Units each side (0.24 mL)
- Total 30 Units
Children 19 kg or more Usual dose 40 Units total per session
Step by step
- Parotid gland 12 Units each side (0.48 mL)
- Submandibular gland 8 Units each side (0.32 mL)
- Total 40 Units
Children 23 kg or more Usual dose 50 Units total per session
Step by step
- Parotid gland 15 Units each side (0.6 mL)
- Submandibular gland 10 Units each side (0.4 mL)
- Total 50 Units
Children 27 kg or more Usual dose 60 Units total per session
Step by step
- Parotid gland 18 Units each side (0.72 mL)
- Submandibular gland 12 Units each side (0.48 mL)
- Total 60 Units
Children 30 kg or more Usual dose 75 Units total per session
Step by step
- Parotid gland 22.5 Units each side (0.9 mL)
- Submandibular gland 15 Units each side (0.6 mL)
- Total 75 Units
Upper limb muscle stiffness (spasticity)
Adults Highest dose 400 Units total
- Up to 400 Units total, divided among affected muscles
- Repeat no sooner than every 12 weeks.
- Per muscle: flexor digitorum superficialis 25 Units-100 Units (2 sites)
- Flexor digitorum profundus 25 Units-100 Units (2 sites)
- Flexor carpi radialis 25 Units-100 Units (1-2 sites)
- Flexor carpi ulnaris 20 Units-100 Units (1-2 sites)
- Brachioradialis 25 Units-100 Units (1-3 sites)
- Biceps 50 Units-200 Units (1-4 sites)
- Brachialis 25 Units-100 Units (1-2 sites)
- Pronator quadratus 10 Units-50 Units (1 site)
- Pronator teres 25 Units-75 Units (1-2 sites)
- Flexor pollicis longus 10 Units-50 Units (1 site)
- Adductor pollicis 5 Units-30 Units (1 site)
- Flexor pollicis brevis/opponens pollicis 5 Units-30 Units (1 site)
Good to know
In patients not previously treated with a botulinum toxin, begin at the low end of the range
Children 2 years and older Highest dose 200 Units per single upper limb
- Up to 8 Units/kg divided among affected muscles per single upper limb
- 16 Units/kg if both upper limbs are treated
- Repeat no sooner than every 12 weeks.
- Per muscle (Units/kg, maximum Units, sites): brachioradialis 1-2, 50, 1-2
- Biceps 2-3, 75, 1-3
- Brachialis 1-2, 50, 1-2
- Flexor carpi radialis 1, 25, 1
- Flexor carpi ulnaris 1, 25, 1
- Pronator quadratus 0.5, 12.5, 1
- Pronator teres 1-2, 50, 1-2
- Flexor digitorum superficialis 1, 25, 1
- Flexor digitorum profundus 1, 25, 1
- Flexor pollicis longus 1, 25, 1
- Adductor pollicis 0.5, 12.5, 1
- Flexor pollicis brevis/opponens pollicis 0.5, 12.5, 1
Neck muscle spasms (cervical dystonia)
For adults · Starting dose
Starting dose 120 Units per treatment session
- Repeat generally no more often than every 12 weeks
Good to know
Previously treated patients: consider past dose, response, duration of effect and adverse events
Uncontrolled eyelid spasms (blepharospasm)
For adults · Starting dose
Starting dose 50 Units (25 Units per eye)
Highest dose 100 Units per treatment session
- Repeat no more often than every 12 weeks
Good to know
Previously treated with botulinum toxin A: consider past dose, response, duration of effect and adverse events
Upper facial lines
Adults Highest dose 64 Units
- 64 Units: 20 Units for GL, 20 Units for HFL, 24 Units for LCL
- Retreat no more frequently than every three months
GL stands for glabellar lines.
HFL stands for horizontal forehead lines.
LCL stands for lateral canthal lines.
Adults, frown lines between the eyebrows Usual dose 4 Units into each of 5 sites Highest dose 20 Units
- 4 Units into each of 5 sites (2 in each corrugator muscle, 1 in the procerus muscle)
Adults, forehead lines treated with frown lines Highest dose 40 Units
- 4 Units into each of 5 HFL sites (20 Units) and 4 Units into each of 5 GL sites (20 Units)
GL stands for glabellar lines.
HFL stands for horizontal forehead lines.
Side Effects
Side effects vary by what is being treated. Common ones include:
Common side effects
- Dry mouth
- Injection site pain or bruising
- Neck pain and muscle weakness (cervical dystonia)
- Trouble swallowing (cervical dystonia)
- Drooping eyelid, dry eye or blurred vision (blepharospasm)
- Cold-like symptoms such as nasopharyngitis, bronchitis or upper respiratory infection
- Headache
- Injection site pain, bruising or hematoma (blood collection under the skin)
When to get medical help
- Get medical help right away for trouble swallowing, speaking or breathing, which can happen hours to weeks after injection.
- Seek care for widespread muscle weakness, double or blurred vision, drooping eyelids or loss of bladder control.
- Get emergency help for signs of a serious allergic reaction such as hives, swelling, wheezing or trouble breathing.
- Tell your doctor about eye pain or irritation after eyelid treatment, as corneal damage can occur.
- Seizures were reported in adults treated for upper limb spasticity.
Seek care right away for swallowing, speech or breathing trouble, widespread weakness, or signs of allergic reaction.
Warnings and Precautions
- Spread of toxin effect: weakness, vision changes and swallowing or breathing problems can occur far from the injection site, hours to weeks later.
- Swallowing and breathing: risk is higher with existing swallowing, breathing or neuromuscular conditions. Dysphagia can last months and sometimes require a feeding tube.
- Allergic reactions: serious reactions including anaphylaxis have been reported.
- Eyes: after eyelid treatment, reduced blinking can injure the cornea. Use caution with narrow-angle glaucoma risk.
- Frown line treatment: eyelid drooping (ptosis) can occur, so doses and injection placement matter.
- Units: Xeomin units cannot be converted to other botulinum toxins.
- Human albumin: the product contains it, with an extremely remote risk of viral transmission.
Interactions
Some medicines can increase Xeomin’s muscle-weakening effect.
- Aminoglycoside antibiotics and similar agents: can strengthen the toxin’s effect.
- Muscle relaxants: may cause excessive weakness.
- Anticholinergic drugs: may increase body-wide anticholinergic effects.
- Other botulinum toxins: excessive weakness is possible if given close together.
Interactions Listed in the FDA-Approved Label
From the IncobotulinumtoxinA Injection prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
-
Aminoglycosides and other agents interfering with neuromuscular transmission For example: tubocurarine-type muscle relaxantsWhat happensThese agents may potentiate the effect of the toxin.What to doCo-administer only with caution and close observation.
-
Anticholinergic drugsWhat happensUse after administration of XEOMIN may potentiate systemic anticholinergic effects.
-
Other botulinum neurotoxin productsWhat happensThe effect of giving different botulinum toxin products at the same time or within several months of each other is unknown; excessive neuromuscular weakness may be exacerbated.
-
Muscle relaxantsWhat happensExcessive weakness may be exaggerated by a muscle relaxant given before or after XEOMIN.
Read the label’s full interactions text
7 DRUG INTERACTIONS Aminoglycosides or other agents that interfere with neuromuscular transmission may potentiate the effect of XEOMIN; co-administer only with caution and close observation 7.1 Aminoglycosides and Other Agents Interfering with Neuromuscular Transmission Co-administration of XEOMIN and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., tubocurarine-type muscle relaxants) should only be performed with caution as these agents may potentiate the effect of the toxin. 7.2 Anticholinergic Drugs Use of anticholinergic drugs after administration of XEOMIN may potentiate systemic anticholinergic effects. 7.3 Other Botulinum Neurotoxin Products The effect of administering different botulinum toxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin. 7.4 Muscle Relaxants Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of XEOMIN.
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before You Start
- Do not use with a known allergy to botulinum toxins or the ingredients.
- Do not use with infection at the injection site.
- Tell your doctor about swallowing or breathing problems, ALS, myasthenia gravis or Lambert-Eaton syndrome.
- Tell your doctor about eye surgery, narrow-angle glaucoma risk, facial asymmetry or eyelid drooping.
- Pregnancy: use only if the benefit justifies the risk. Animal studies showed harm at high doses.
- Breastfeeding: there are no data on milk or infant effects, so discuss it with your doctor.
- Children: not established for several uses, and not for those under 2 years.
- Older adults: no overall differences seen, though increased sensitivity cannot be ruled out.
Overdose
Too much Xeomin can cause widespread muscle weakness and, in severe cases, paralysis of breathing muscles that may need breathing support. Symptoms may not appear right away, so a person should be medically monitored for several weeks. Antitoxin exists but will not reverse effects already present.
How Your Body Processes It
At recommended doses, Xeomin cannot be detected in the blood after injection into muscle or salivary glands. That means its action stays mostly local to the injection area.
Storage
Store unopened vials of XEOMIN at or below 25°C (77°F). Refrigeration of unopened vials is not required. Stored in a refrigerator at 2°C to 8°C (36°F to 46°F) for up to 24 hours until time of use .
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
IncobotulinumtoxinA Injection: Pharmacist Answers to Common Questions
Quick, plain-English answers to the questions patients ask most about IncobotulinumtoxinA Injection — the kind of thing our pharmacy team would talk through with you at the counter.
What is Xeomin used for?
How is Xeomin given and how often?
What side effects should I expect?
When should I get medical help after an injection?
Can I get Xeomin if I take other medicines?
Is Xeomin safe during pregnancy or breastfeeding?
Is IncobotulinumtoxinA injection available over the counter?
When was IncobotulinumtoxinA injection first available?
Who makes IncobotulinumtoxinA injection?
What is the brand name of IncobotulinumtoxinA injection?
What is the generic name of Xeomin?
What drug class is IncobotulinumtoxinA injection?
What strengths does IncobotulinumtoxinA injection come in?
Where can I read the IncobotulinumtoxinA injection prescribing information (package insert)?
Is IncobotulinumtoxinA injection gluten free?
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Ask Anything About IncobotulinumtoxinA Injection
Skip the scrolling. Ask in your own words and get an answer from IncobotulinumtoxinA Injection’s FDA label and our pharmacists’ own work.
Name another drug or a supplement in your question and we check both.
AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
- Sources: IncobotulinumtoxinA Injection’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
- Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
- Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
- Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.
More About IncobotulinumtoxinA Injection on HelloPharmacist
Still have a question? A licensed pharmacist answers for free, as soon as they can.IncobotulinumtoxinA Injection Forms and Strengths (How It Comes)
IncobotulinumtoxinA Injection comes in 1 dose form, the injection. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see IncobotulinumtoxinA Injection inactive ingredients by manufacturer.
Injection
How this form is used
- Xeomin is used for chronic sialorrhea and upper limb spasticity in people 2 years and older.
- Xeomin is used for cervical dystonia and blepharospasm in adults.
- Xeomin is used for temporary improvement of upper facial lines in adults.
- Xeomin is injected into muscles or, for drooling, into the parotid and submandibular salivary glands.
- Xeomin is mixed (reconstituted) before use, for one patient and one session only.
- Xeomin repeat treatments are spaced at least 12 to 16 weeks apart for most uses, and no more often than every three months for facial lines.
- Xeomin units are not interchangeable with other botulinum toxin products.
IncobotulinumtoxinA Injection on the U.S. Market: Products, Makers and Brands
How IncobotulinumtoxinA Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
2 companies list 8 IncobotulinumtoxinA Injection product records with the FDA, mostly as injection; the earliest marketing or approval year on record is 2010. The one brand name in the directory today is Xeomin; the rest are generics.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How Widely IncobotulinumtoxinA Injection Is Used (Medicaid Data)
How many IncobotulinumtoxinA Injection prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.
How commonly is IncobotulinumtoxinA Injection prescribed? Of the 1,682 medications we measure, IncobotulinumtoxinA Injection ranks #989 by Medicaid prescriptions — more than 41% of them.
Utilization by IncobotulinumtoxinA Injection product
Pick a strength and form to see its own numbers. Brand and generic versions are counted together.
Other IncobotulinumtoxinA Injection products: packs and listings not matched to one strength and form
3 of 10 listed NDCs had Medicaid claims.
Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.
Source: Medicaid State Drug Utilization Data (CMS), all states. 3 of the 10 listed IncobotulinumtoxinA Injection NDCs had Medicaid claims.
Compare IncobotulinumtoxinA Injection Products
A representative set of FDA-listed product records for IncobotulinumtoxinA Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 50 [USP'U] | Intramuscular | Merz North America, Inc. × 2 listings | BLA | View NDC → |
| 100 [USP'U] | Intramuscular | Merz North America, Inc. | BLA | View NDC → |
| 50 [USP'U] | Intramuscular | Merz Pharmaceuticals, LLC × 2 listings | BLA | View NDC → |
| 100 [USP'U] | Intramuscular | Merz Pharmaceuticals, LLC × 2 listings | BLA | View NDC → |
| 200 [USP'U] | Intramuscular | Merz Pharmaceuticals, LLC | BLA | View NDC → |
Showing 8 of 8 products — FDA National Drug Code Directory. See every product, package size and price: browse all 8 IncobotulinumtoxinA Injection NDCs →
IncobotulinumtoxinA Injection Side Effects Reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for IncobotulinumtoxinA Injection — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists IncobotulinumtoxinA Injection in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
IncobotulinumtoxinA Injection FDA Approval History
How IncobotulinumtoxinA Injection went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
IncobotulinumtoxinA Injection Recall History
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no IncobotulinumtoxinA recalls since July 2021.
✅No IncobotulinumtoxinA recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.
IncobotulinumtoxinA Injection Supply and Shortage Status
Whether IncobotulinumtoxinA Injection is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
IncobotulinumtoxinA Injection Brand Names
IncobotulinumtoxinA Injection has one brand name on record: Xeomin. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.
Who Makes IncobotulinumtoxinA Injection: Manufacturers and Labelers
2 companies list IncobotulinumtoxinA Injection products with the FDA. By number of product records, the largest are Merz Pharmaceuticals, LLC, Merz North America, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Sources for This IncobotulinumtoxinA Injection Page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Merz North America, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →